Based on results from the “gold standard” HIE animal model, RLS-0071 decreases the area of brain infraction by 50% and dramatically improves neurocognitive outcomes, even to adult age. As seen below, there is little visible difference between the normal rat pup brain and the brain of a rat treated with RLS-0071, while untreated rats and rats treated with hypothermia show large areas of dead brain tissue.
RLS-0071 also dramatically improves neurocognitive function of HIE-induced rats. Below are test results of rat ability to remember escape hole locations. HIE-induced rats treated with RLS-0071 are clearly smarter.
There are currently no pharmaceutical approaches to treat birth asphyxia. RLS-0071 is the first anti-inflammatory/antioxidant compound studied for HIE. As such, RLS-0071 represents a new treatment approach with a focus on preventing brain damage. RLS-0071 is designed to decrease reperfusion injury via our dual targeting mechanisms of action that inhibits complement activation and innate inflammatory processes and oxidative damage.
Acute lung injury (ALI) associated with COVID-19 is the most frequent cause of death related to the infection, with limited benefit shown from current treatments.Learn More
Hypoxic-ischemic encephalopathy (HIE) is a type of newborn brain damage caused by oxygen deprivation and limited blood flow.Learn More
A hemolytic transfusion reaction is a serious complication that can occur after a blood transfusion.Learn More
Autoimmune hemolytic anemia is a group of disorders characterized by a malfunction of the immune system that produces autoantibodies, which attack red blood cells as if they were substances foreign to the body.Learn More